Therefore, dual inhibitors of SGLT1 and SGLT2 (such as sotagliflozin and LX-2761) are being developed for the treatment of diabetes (Powell et al., 2017; Sands et al., 2015). Here, SLC5A2 is linked to diabetes mellitus.